- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04144192
Pharmacokinetic Study of Lidocaine Patch 1.8% Lidocaine Patch 5% (Lidoderm®) in Healthy Subjects
October 28, 2019 updated by: Scilex Pharmaceuticals, Inc.
Phase 1, Randomized, Comparative Pharmacokinetic Study of Bolus Intravenous Lidocaine 0.7 mg/kg, Lidocaine Patch 1.8%, and Lidocaine Patch 5% (Lidoderm®) in Healthy Subjects
The purpose of this study is to characterize the comparative single-dose pharmacokinetics (bioequivalence) of lidocaine patch 1.8% (investigational product) versus Lidoderm® (lidocaine patch 5%,reference product).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
58
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Must be healthy based on by medical history, laboratory work, and physical exam
- Be at least 18 years of age
- If childbearing potential, use of acceptable form of birth control
- In the case of females of childbearing potential, have a negative serum pregnancy test
Exclusion Criteria:
- Use of a prescription medication within 14 days or over-the-counter products within 7 days prior to administration of study medication
- Known hypersensitivity or allergy to any of the components of the lidocaine topical system formulation
- Any serious illness in the 4 weeks preceding the beginning of treatment that resulted in missed work or hospitalization
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Lidocaine Patch (Sequence AB)
Subjects received all study treatments: a bolus IV injection of 0.7 mg/kg lidocaine IV in the morning of study Day 1, and then lidocaine patch treatment on Day 8 and Day 15.
The sequence in which they received patch treatment was determined by random assignment.
For subjects in Arm 1, 3 lidocaine 1.8% patches were applied on Day 8 and 3 Lidoderm® 5% patches were applied on Day 15.
|
Other Names:
Other Names:
|
Experimental: Lidocaine Patch (Sequence BA)
Subjects received all study treatments: a bolus IV injection of 0.7 mg/kg lidocaine IV in the morning of study Day 1, and then lidocaine patch treatment on Day 8 and Day 15.
The sequence in which they received patch treatment was determined by random assignment.
For subjects in Arm 2, 3 Lidoderm® 5% patches were applied on Day 8 and 3 lidocaine 1.8% patches were applied on Day 15.
|
Other Names:
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Peak plasma concentration (Cmax) of lidocaine
Time Frame: 0, 2, 4, 6, 9, 10, 11, 12, 13, 14, 16, 18, 20, 22, 24, 48 hours post-dose
|
Peak plasma concentration of lidocaine after application of 3 patches for 12 hours
|
0, 2, 4, 6, 9, 10, 11, 12, 13, 14, 16, 18, 20, 22, 24, 48 hours post-dose
|
Area under the Plasma Concentration-Time Curve (AUC) from Time 0 to Time 48 hours
Time Frame: 0, 2, 4, 6, 9, 10, 11, 12, 13, 14, 16, 18, 20, 22, 24, 48 hours post-dose
|
Area under the plasma concentration versus time curve from 0 to 48 hours of lidocaine in plasma
|
0, 2, 4, 6, 9, 10, 11, 12, 13, 14, 16, 18, 20, 22, 24, 48 hours post-dose
|
Area under the Plasma Concentration-Time Curve (AUC) from Time 0 to Time Infinity
Time Frame: 0, 2, 4, 6, 9, 10, 11, 12, 13, 14, 16, 18, 20, 22, 24, 48 hours post-dose
|
Area under the plasma concentration versus time curve from 0 to infinite time of lidocaine in plasma
|
0, 2, 4, 6, 9, 10, 11, 12, 13, 14, 16, 18, 20, 22, 24, 48 hours post-dose
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 28, 2014
Primary Completion (Actual)
July 24, 2014
Study Completion (Actual)
July 24, 2014
Study Registration Dates
First Submitted
October 28, 2019
First Submitted That Met QC Criteria
October 28, 2019
First Posted (Actual)
October 30, 2019
Study Record Updates
Last Update Posted (Actual)
October 30, 2019
Last Update Submitted That Met QC Criteria
October 28, 2019
Last Verified
October 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Sensory System Agents
- Anesthetics
- Membrane Transport Modulators
- Anesthetics, Local
- Voltage-Gated Sodium Channel Blockers
- Sodium Channel Blockers
- Lidocaine
Other Study ID Numbers
- SCI-LIDO-PK-001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Lidocaine 2% Injectable Solution
-
McMaster UniversitySt. Joseph's Healthcare HamiltonWithdrawnIntravenous Lidocaine for Post-Operative Pain Control in Patients Undergoing Bariatric Bowel SurgeryBariatric Surgery Candidate
-
University of British ColumbiaCompletedMigraine in Children | Posttraumatic HeadacheCanada
-
Develi Devlet HastanesiUnknownAnesthesia, Local | Patient Satisfaction | Anesthesia Recovery Period | Cataract Surgery | Anesthesia; Adverse Effect | AkinesiaTurkey
-
Menoufia UniversityRecruitingPostoperative Sore ThroatEgypt
-
University of SaskatchewanCompletedPharyngitis | Intubation, Intratracheal | Lidocaine | Ropivacaine | Post-operative Sore ThroatCanada
-
Medical University of SilesiaCompletedTemporomandibular DisorderPoland
-
Sintetica SARecruitingHernia, Inguinal | Flat FootItaly, Spain
-
Alcon ResearchTerminatedOcular Hypertension | Open-angle Glaucoma
-
Paola M Zamora MunozCompletedAcute Pain | Knee ArthroscopyMexico
-
Pamukkale UniversityCompletedPrimary DysmenorrheaTurkey